Loading clinical trials...
Loading clinical trials...
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Conditions
Interventions
MT-3724 Phase 1
MT-3724 Phase 2
Locations
41
United States
University of Arizona
Tucson, Arizona, United States
Innovative Clinical Research Institute, LLC
Whittier, California, United States
21st Century Oncology - Jacksonville
Jacksonville, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
Orlando Health, Inc.
Orlando, Florida, United States
BRCR Medical Center
Plantation, Florida, United States
Start Date
February 1, 2015
Primary Completion Date
March 22, 2021
Completion Date
March 22, 2021
Last Updated
August 18, 2022
NCT07162181
NCT02869529
NCT05621148
NCT03207555
NCT04210219
NCT03190330
Lead Sponsor
Molecular Templates, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions